NPPA SETS NEW AFFORDABLE RANGE FOR DRUGS : CUTS OVER PRICING 

Date:

Share post:

NPPA SETS NEW AFFORDABLE RANGE FOR DRUGS : CUTS OVER PRICING 

PharmaGenDrx News Bureau – 05th August 2025, 

3:00 PM IST

 To ensure affordability and supply of essential medicines National Pharmaceutical Pricing Authority (NPPA) sets out to deliver a robust move in managing exploitation of prices. 

NPPA has recently issued three notices to tackle this situation, addressing ceiling price and retail price for over 40 drugs. This has been done under Drugs Price Control Order (DPCO) 2013. The notice issued on 1st August authorises the ceiling prices of scheduled drugs, for all manufacturers of scheduled and generic medicines have been conveyed to set or revise their ceiling prices according to the new mandate for commonly used drugs such as Ipratropium and Diltiazem. 

The next mandate addressed, retail prices for non scheduled new marketed drugs. This focused on the combined drug therapy strategies. 

Market based retailed price competition was addressed in another mandate, via market analysis. The objective of this mandate was to lower the price of drugs to an affordable  rate ensuring the fair pricing. This was done using Moving Annual Turn-over(MAT) and Price To Retailers (PTR) data. More than thirty such commonly used drugs were addressed and their percentage price was reduced such as Vit D3 oral drops. 

With the growing demands of safeguarding  public health, such steps taken by NPPA restores the faith of the residents in  the government, along with highlighting NPPA’s commitment towards curbing exploitation and improving transparency. 

By Sharon Bose and Arundhuti Chatterjee 

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related articles

Dabur India Plant Under US FDA Scanner Over Contamination Concerns

The United States Food and Drug Administration (US FDA) has flagged serious concerns at Dabur India's manufacturing facility...

FDA Approves Wockhardt’s Novel Antibiotic ZAYNICH™️ for cUTI

Wockhardt Limited  announced that the U.S. Food and Drug Administration (FDA) has approved ZAYNICH™ (cefepimeand zidebactam), a novel intravenous antibiotic...

Relief for Patients: NPPA Fixes Ceiling Prices for 30 Essential Medicines

The National Pharmaceutical Pricing Authority (NPPA) has notified ceiling prices for 30 essential fixed-dose combination medicines under the...

FDA Draft Guidance Aims to Reduce Animal Testing for Cancer Drugs

The U.S. Food and Drug Administration (FDA) issued a new draft guidance aimed at reducing unnecessary animal testing...